0001193125-24-161664.txt : 20240614 0001193125-24-161664.hdr.sgml : 20240614 20240614163056 ACCESSION NUMBER: 0001193125-24-161664 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240611 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing FILED AS OF DATE: 20240614 DATE AS OF CHANGE: 20240614 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIORA THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001580063 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 273950390 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39334 FILM NUMBER: 241045352 BUSINESS ADDRESS: STREET 1: 4330 LA JOLLA VILLAGE DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92122 BUSINESS PHONE: 855-293-2639 MAIL ADDRESS: STREET 1: 4330 LA JOLLA VILLAGE DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92122 FORMER COMPANY: FORMER CONFORMED NAME: PROGENITY, INC. DATE OF NAME CHANGE: 20150617 FORMER COMPANY: FORMER CONFORMED NAME: ASCENDANT MDX, INC. DATE OF NAME CHANGE: 20130625 8-K 1 d805555d8k.htm 8-K 8-K
false 0001580063 0001580063 2024-06-11 2024-06-11

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 11, 2024

 

 

Biora Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-39334   27-3950390
(State or Other Jurisdiction
of Incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

 

4330 La Jolla Village Drive, Suite 300  
San Diego, California   92122
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s Telephone Number, Including Area Code: (833) 727-2841

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange
on which registered

Common Stock, par value $0.001 per share   BIOR   The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

As previously disclosed, on December 11, 2023, Biora Therapeutics, Inc. (the “Company”) received written notice from the Listing Qualifications Staff (“Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the 30 consecutive business days ended December 11, 2023, the Company’s market value of listed securities (“MVLS”) closed below the $50 million MVLS threshold for continued listing on The Nasdaq Global Market under Nasdaq Listing Rule 5450(b)(2)(A) (the “MVLS Rule”). As provided in the Nasdaq rules, the Company was granted 180 calendar days, or until June 10, 2024, to regain compliance with the MVLS Rule. The Company did not regain compliance with the MVLS Rule by June 10, 2024 and, accordingly, on June 11, 2024, the Staff notified the Company that its securities were subject to delisting from Nasdaq unless the Company timely requests a hearing before the Nasdaq Hearing Panel (the “Panel”).

The Company plans to timely request a hearing before the Panel, which request will stay any further action by Nasdaq pending the hearing and the expiration of any extension that may be granted to the Company following the hearing. At the hearing, the Company will present its plan to evidence compliance with all applicable listing criteria, including the MVLS Rule, and request an extension of time to do so. The Panel has the authority to grant the Company an extension of up to 180 days from the date of the Staff’s delist determination, or December 9, 2024. The Company is considering all options available to it to regain compliance with the MVLS Rule; however, there can be no assurance that the Panel will grant the Company’s request for continued listing or that the Company will be able to evidence compliance within the period of time that may be granted by the Panel.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Current Report on Form 8-K (“Form 8-K”) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the Company’s intent to request a hearing before a Panel and the Company’s expectations regarding how long it may remain listed on The Nasdaq Global Market. The Company’s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, including the risk that the Company may not be successful in its appeal to a Panel, the risk that the Company may not otherwise meet the requirements for continued listing under the Nasdaq Listing Rules, the risk that Nasdaq may not grant the Company relief from delisting if necessary, and the risk that the Company may not ultimately meet applicable Nasdaq requirements if any such relief is necessary, among other risks and uncertainties. These and other important factors discussed under the caption “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the U.S. Securities and Exchange Commission (“SEC”), and the Company’s other filings with the SEC, including the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2024, could cause actual results to differ materially from those indicated by the forward-looking statements made in this Form 8-K. Any forward-looking statements speak only as of the date of this Form 8-K and are based on information available to the Company as of the date of this Form 8-K, and the Company assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: June 14, 2024   Biora Therapeutics, Inc.
    By:  

/s/ Eric d’ Esparbes

      Eric d’ Esparbes
      Chief Financial Officer
 EX-101.SCH 2 bior-20240611.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 bior-20240611_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 4 bior-20240611_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Document and Entity Information
Jun. 11, 2024
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001580063
Document Type 8-K
Document Period End Date Jun. 11, 2024
Entity Registrant Name Biora Therapeutics, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-39334
Entity Tax Identification Number 27-3950390
Entity Address, Address Line One 4330 La Jolla Village Drive
Entity Address, Address Line Two Suite 300
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92122
City Area Code (833)
Local Phone Number 727-2841
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.001 per share
Trading Symbol BIOR
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://bioratherapeutics.com//20240611/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports bior-20240611.xsd bior-20240611_lab.xml bior-20240611_pre.xml d805555d8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d805555d8k.htm": { "nsprefix": "bior", "nsuri": "http://bioratherapeutics.com/20240611", "dts": { "schema": { "local": [ "bior-20240611.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "labelLink": { "local": [ "bior-20240611_lab.xml" ] }, "presentationLink": { "local": [ "bior-20240611_pre.xml" ] }, "inline": { "local": [ "d805555d8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://bioratherapeutics.com//20240611/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2024-06-11_to_2024-06-11", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d805555d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2024-06-11_to_2024-06-11", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d805555d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://bioratherapeutics.com//20240611/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://bioratherapeutics.com//20240611/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://bioratherapeutics.com//20240611/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://bioratherapeutics.com//20240611/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://bioratherapeutics.com//20240611/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://bioratherapeutics.com//20240611/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://bioratherapeutics.com//20240611/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://bioratherapeutics.com//20240611/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://bioratherapeutics.com//20240611/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://bioratherapeutics.com//20240611/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://bioratherapeutics.com//20240611/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://bioratherapeutics.com//20240611/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://bioratherapeutics.com//20240611/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://bioratherapeutics.com//20240611/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://bioratherapeutics.com//20240611/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://bioratherapeutics.com//20240611/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://bioratherapeutics.com//20240611/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://bioratherapeutics.com//20240611/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://bioratherapeutics.com//20240611/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://bioratherapeutics.com//20240611/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://bioratherapeutics.com//20240611/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://bioratherapeutics.com//20240611/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://bioratherapeutics.com//20240611/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://bioratherapeutics.com//20240611/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0001193125-24-161664-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-161664-xbrl.zip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d805555d8k_htm.xml IDEA: XBRL DOCUMENT 0001580063 2024-06-11 2024-06-11 false 0001580063 8-K 2024-06-11 Biora Therapeutics, Inc. DE 001-39334 27-3950390 4330 La Jolla Village Drive Suite 300 San Diego CA 92122 (833) 727-2841 false false false false Common Stock, par value $0.001 per share BIOR NASDAQ true false